Investors in Salix Pharmaceuticals (NASDAQ: SLXP )
might have had some upset stomachs in the days leading up to today's
announcement of positive results from the TARGET-3 study of Xifaxan in
IBS-D. Although a medical journal review from mid-2012 had suggested
that Xifaxan would pass this study of long-term retreatment, there are
hundreds of millions of high-margin incremental sales riding on Salix
ultimately securing FDA approval for a drug that has had a tough route
to approval for this large indication.
Read more here:
Why Salix Pharmaceuticals' Good Data Wasn't Great
Showing posts with label Furiex. Show all posts
Showing posts with label Furiex. Show all posts
Wednesday, July 2, 2014
Saturday, May 10, 2014
Seeking Alpha: There May Be More Moves Involving Salix Before The Year's Done
There has been ample M&A activity in the drug sector, with companies like Valeant (VRX), Endo International (ENDP), and Actavis (ACT) all looking to add scale and exploit low interest rates and low tax rates. Salix (SLXP) has been busy too, paying around $2.6 billion to acquire Santarus
and adding scale in primary care and GI drugs. Salix's valuation
suggests that investors may still be expecting more action, as Salix's
focused portfolio and high effective tax rate could make it a player
either as an acquirer seeking a tax inversion deal or a target.
Read the full article here:
There May Be More Moves Involving Salix Before The Year's Done
Read the full article here:
There May Be More Moves Involving Salix Before The Year's Done
Labels:
Furiex,
Salix Pharmaceuticals,
Seeking Alpha
Monday, April 28, 2014
The Motley Fool: For Forest Labs, Inc, Deals Are Coming Fast And Furiex
This is definitely a season of deals in the health care space, with Forest Labs (NYSE: FRX ) choosing to add another asset to its GI business ahead of its anticipated merger with Actavis (NYSE: ACT ) . Forest Labs is offering a significant premium for Furiex Pharmaceuticals (NASDAQ: FURX )
and there are still FDA-related risks in play, but it seems like a
reasonable offer for what could prove to be a highly synergistic asset.
Read the full article here:
For Forest Labs, Inc, Deals Are Coming Fast And Furiex
Read the full article here:
For Forest Labs, Inc, Deals Are Coming Fast And Furiex
Tuesday, December 3, 2013
Seeking Alpha: Another Setback For Lexicon, But Not In Diabetes
Lexicon Pharmaceuticals (LXRX)
continues to see its pipeline winnowed down by clinical trial failures.
A prospective drug for rheumatoid arthritis basically went away last
year, and it was just about two months ago that the company announced
that LX 1032 (telotristat etiprate) had failed to show significant
efficacy in a Phase II study in ulcerative colitis. Now there's another
piece of bad news to digest, as the company announced Tuesday morning
that its Phase II study of LX 1033 in IBS-D (diarrhea-prominent
irritable bowel syndrome) failed to meet its primary endpoint.
Lexicon may, or may not, go forward with another study of LX 1033 on the basis of post-hoc analysis that appears to suggest some efficacy. Either way, it's not a tremendously significant part of the overall valuation. What's far more important is whether the company can seal the deal and sign up a partner to fund a Phase III study of the company's LX 4211 SGLT-1/-2 inhibitor for diabetes. Lexicon still appears to be meaningfully undervalued on the basis of the potential value of LX 4211, but Lexicon is increasingly turning into a one-product story with a concomitant increase in the risks.
Want to read more? Click here:
Another Setback For Lexicon, But Not In Diabetes
Lexicon may, or may not, go forward with another study of LX 1033 on the basis of post-hoc analysis that appears to suggest some efficacy. Either way, it's not a tremendously significant part of the overall valuation. What's far more important is whether the company can seal the deal and sign up a partner to fund a Phase III study of the company's LX 4211 SGLT-1/-2 inhibitor for diabetes. Lexicon still appears to be meaningfully undervalued on the basis of the potential value of LX 4211, but Lexicon is increasingly turning into a one-product story with a concomitant increase in the risks.
Want to read more? Click here:
Another Setback For Lexicon, But Not In Diabetes
Labels:
Furiex,
Lexicon Pharmaceuticals,
Seeking Alpha
Subscribe to:
Posts (Atom)